Floatz logo

Tipranavir

HIV-Associated Lipodystrophy Syndrome

Kirby InstituteSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HIV-Associated Lipodystrophy Syndrome cohort.

Asset / SponsorPhaseRating
Efavirenz
Juan A. Arnaiz
Phase 4A
Lamivudine
Thomas Benfield
Phase 4BBB
PRAVASTATIN
Kirby Institute
Phase 4BBB
ZIDOVUDINE
Kirby Institute
Phase 4BBB
Abacavir
Kirby Institute
Phase 4BBB

View all 50 →

Same molecule, other indications

Tipranavir is also rated in:

cardiovascular disorderDormant
BB
Indicative ·
68 / 100
View asset →
liver failureDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →